1. Consenso mexicano de linfoma de Hodgkin
- Author
-
Aldo Mujica-Martínez, Luis Arteaga-Ortiz, José Luis Álvarez-Vera, Adela Segura-García, Ana K Hernández-Colín, Rodrigo Reséndiz-Olea, Mario Alberto Martínez-Ramírez, Karina Silva-Vera, Luisa Banda-García, Martha Alvarado-Ibarra, Sergio José Loera-Fragoso, Yayra M Pichardo-Cepín, María Eugenia Espitia-Ríos, Ana Carolina-Reynoso, José Antonio de la Peña-Celaya, Wilfrido Herrera-Olivares, Pamela Elena Báez-Islas, Elvia Jacobo-Medrano, Luara L Arana-Luna, Eduardo Romero-Martínez, Óscar Teomitzi-Sánchez, Karen D Pérez-Gómez, Alinka Socorro García-Camacho, Andrea I Milán-Salvatierra, Ana Laura Tapia-Enríquez, Shendel P Vilchis-González, Liliana Medina-Guzmán, Juan P Macías-Flores, Orlando Gabriel Palma-Moreno, Lidia V Guerra-Alarcón, Luisa Ma. Alcivar-Cedeño, Leire Montoya-Jiménez, Eugenia Patricia Paredes-Lozano, Denisse Jocelyn Fermín-Caminero, Jocelyn Aguilar-Luevano, Juan Manuel Pérez-Zúñiga, Flavio Rojas-Castillejos, Juan J Orellana-Garibay, Hilda Romero-Rodelo, Lorena Nava-Villegas, Javier de Jesús Morales-Adrián, Willy Flores-Patricio, Atenas Villela-Peña, Eleazar Hernández-Ruiz, Gabriela Cesarman-Maus, Pedro G Guzmán-Mora, and Fredy Tepepa-Flores
- Subjects
business.industry ,General Medicine ,Disease ,medicine.disease ,Hodgkin's lymphoma ,Lymphoma ,Regimen ,Immune system ,medicine.anatomical_structure ,immune system diseases ,Pathognomonic ,hemic and lymphatic diseases ,medicine ,Cancer research ,business ,Reprogramming ,B cell - Abstract
Hodgkin's lymphoma is due to the clonal transformation of cells originating from B lymphocytes, generating the pathognomonic binucleate Reed-Sternberg cells. Hodgkin's lymphoma is a B cell disease with a bimodal distribution, with higher incidence in adolescence and the third decade of life, showing a second peak in people over 55 years of age. Classic Hodgkin lymphoma cells routinely undergo gene expression reprogramming, as they lose the expression of most of the typical B-cell genes and acquire the expression of multiple genes that are typical of other types of cells in the immune system. The treatment algorithm will depend on whether it is classic or predominantly lymphocytic HL, if it is early stage with unfavorable prognostic markers or not, the initial management regimen, and whether there is bulky disease, among the most relevant variables.
- Published
- 2023
- Full Text
- View/download PDF